Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia
Objectives: We investigated seroreactivity by using a commercial SARS-CoV-2 ELISA test in samples collected from different groups of individuals, including patients diagnosed to have Dengue, Zika, and Chikungunya infection between 2015 and 2019, from an endemic area in the Caribbean Colombian region...
- Autores:
-
Faccini Martínez, Álvaro Adolfo
Rivero, Ricardo
Garay Montalvo, Evelin
García Pérez, Alejandra
Mattar Velilla, Ameth Salim
Botero, Yesica
Galeano Anaya, Ketty Esther
Miranda Regino, Jorge Luis
Martínez Bravo, Caty Milena
Guzmán Terán, Camilo Antonio
Contreras, Héctor
Kerguelen, Hugo
Moscote, María
Brango Tarra, Eimi Johana
Contreras Cogollo, Veronica
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2020
- Institución:
- Corporación Universitaria del Caribe - CECAR
- Repositorio:
- Repositorio Digital CECAR
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.cecar.edu.co:cecar/10831
- Acceso en línea:
- https://repositorio.cecar.edu.co/handle/cecar/10831
- Palabra clave:
- Diagnosis
Endemic diseases
Arbovirus infection
Validation study
- Rights
- openAccess
- License
- Derechos reservados - Corporación Universitaria de Caribe - CECAR
| Summary: | Objectives: We investigated seroreactivity by using a commercial SARS-CoV-2 ELISA test in samples collected from different groups of individuals, including patients diagnosed to have Dengue, Zika, and Chikungunya infection between 2015 and 2019, from an endemic area in the Caribbean Colombian region. Methods: A total of 127 sera samples obtained from six different groups of individuals were included in this study: Group A: patients with confirmed SARS-CoV-2 infection; Group B: patients with symptoms suggestive of COVID-19 or asymptomatic contacts with confirmed patients; Group C: patients with acute or recent dengue virus infection; Group D: patients with acute Zika virus infection; Group E: patients with previous Chikungunya virus infection; and Group F: individuals with exposure to spotted fever group rickettsiae. Results: Overall, group A, group B, and group D showed seroreactivity to SARS-CoV-2 in 92%, 75%, and 26% of samples, respectively; furthermore, group C, group E, and group F showed 100% seronegativity. Conclusions: We found 26% of serological cross-reactivity in patients with acute Zika virus infection by using a commercial SARS-CoV-2 ELISA test. Further studies are needed to evaluate whether serological cross-reaction is maintained with time in nonacute patients with previous exposure to the Zika virus and its effect in SARS-CoV-2 serosurveys in endemic areas for this arbovirus. |
|---|
